Brussels, 2 April 2026   

Almost 40 European, national and regional industry organisations have united to reinforce the critical importance of the Biotech Act II. A joint position paper highlights the need for a dedicated and globally ambitious legislation to deliver biomanufacturing scale‑up and market deployment in Europe.

Europe remains the only major global region without a dedicated biomanufacturing initiative. At a time when global competitors such as the United States, India and China are prioritising biomanufacturing at the highest strategic level, the signatories call for a growth and market‑focused EU Biotech Act II to strengthen competitiveness, resilient value chains and high‑quality employment across Europe.

Actions, including the EU Biotech Act Part I which primarily targets health, have boosted innovation, but a critical gap persists in translating innovation into industrial scale in all sectors.

Signatories will continue to work together to support a shared vision for Europe’s industrial future and to ensure that biomanufacturing plays its full role in delivering long‑term growth and resilience.

Dr. Claire Skentelbery, Director General of EuropaBio commented: “A Biotech Act II dedicated to biomanufacturing is the missing piece of the puzzle for the EU’s global competitiveness from this vital technology. It is essential that we empower all sectors with a thriving EU market, cutting edge capability and ensuring that it is the logical next investment for companies in our champion sectors. We must create our own destiny for biomanufacturing, rather than watching it being delivered elsewhere and the job is not yet done.

Read and download the full press release and joint industry statement